

Changes in cardiac parameters during venetoclax treatment

Authors

Roman Brock,¹ Edit Porpaczy,² Patrick Caron,³ Cathrin Skrabs,² Renate Thalhammer,⁴ Olga Falco,² Ingrid Simonitsch-Klupp,⁵ Ana-Iris Schiefer,⁵ Wolfgang R. Sperr,^{2,6} Karoline V. Gleixner,^{2,6} Martina Schlager,² Peter Valent,^{2,6} Raute Sunder-Plassmann,⁴ Jutta Bergler-Klein,⁷ Katrina Vanura,² Chantal Guillemette,³ Philipp Staber^{2,6} and Ulrich Jäger²

¹Department of Emergency Medicine, Medical University of Vienna, Austria; ²Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria; ³Centre de Recherche du Centre Hospitalier Universitaire de Québec, Université Laval Cancer Research Center and Faculty of Pharmacy, Université Laval, Québec, Ontario, Canada; ⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; ⁵Clinical Institute of Pathology, Medical University of Vienna,

Vienna, Austria; ⁶Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria and ⁷Department of Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria

Correspondence:
U. JÄGER - ulrich.jaeger@meduniwien.ac.at

<https://doi.org/10.3324/haematol.2024.287280>
Received: January 15, 2025.
Accepted: April 15, 2025.
Early view: April 24, 2025.

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license



Supplement: Changes in Cardiac Parameters during Venetoclax Treatment

Supplemental Tables:


	Female (N=20)	Male (N=35)	Overall (N=55)	Therapy line (median - IQR)
Age				
Mean (SD)	67.1 (13.6)	65.8 (12.1)	66.3 (12.6)	
Median (Q1, Q3)	73.2 (58.5, 77.8)	69.2 (58.4, 75.2)	69.4 (58.2, 75.5)	
Diagnosis				3 (2, 5)
CLL	12 (60.0%)	20 (57.1%)	32 (58.2%)	4 (2.5, 6)
AML	2 (10.0%)	5 (14.3%)	7 (12.7%)	3 (2, 3)
DLBCL	4 (20.0%)	7 (20.0%)	11 (20.0%)	2 (1.25, 2.75)
T-PLL	2 (10.0%)	3 (8.6%)	5 (9.1%)	3 (3, 3)

Supplemental Table 1: patient characteristics

Combination therapies	Overall (N=55)
Azacitidin	5 (9.1%)
Azacitidin, Bortezomib	1 (1.8%)
Azacitidin, Ibrutinib	1 (1.8%)
Ibrutinib	1 (1.8%)
MOR00208	4 (7.3%)
Obinutuzumab	17 (30.9%)
Obinutuzumab, Ibrutinib	1 (1.8%)
Rituximab	11 (20.0%)
Rituximab, Cyclophosphamid, Doxorubicin, Vincristin, Prednisolon	2 (3.6%)
Rituximab, Obinutuzumab	1 (1.8%)
Romidepsin	1 (1.8%)
Venetoclax mono	10 (18.2%)

Supplemental Table 2: Various combination therapies

Supplemental Figures:



Supplemental Figure 1: Patients with higher Creatinine levels tend to show higher troponin T levels but still in a venetoclax dose-dependent manner. Color shows creatinine levels in classes.